Microba Life Sciences Ltd (ASX: MAP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Microba Life Sciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$51.76 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
608.96 million
Earnings per share
-0.033
Dividend per share
N/A
Year To Date Return
14.47%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Microba Life Sciences Ltd (ASX: MAP)
Latest News
No posts found.
MAP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Microba Life Sciences Ltd
Microba Life Sciences Ltd. engages in the provision of microbiome testing, supplements and analysis services as well as developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. It operates through the Testing Services and Supplements and Research and Development segments. The company was founded by Gene Tyson and Philip Hugenholtz on January 31, 2017 and is headquartered in Brisbane, Australia.
MAP Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | $0.09 | $0.00 | 0.00% | 95,543 | $0.08 | $0.09 | $0.08 |
| 05 Feb 2026 | $0.09 | $0.00 | 0.00% | 37,280 | $0.09 | $0.09 | $0.09 |
| 04 Feb 2026 | $0.09 | $0.00 | 0.00% | 20,000 | $0.09 | $0.09 | $0.09 |
| 03 Feb 2026 | $0.09 | $0.00 | 0.00% | 54,158 | $0.09 | $0.09 | $0.09 |
| 02 Feb 2026 | $0.09 | $0.00 | 0.00% | 346,793 | $0.09 | $0.09 | $0.09 |
| 30 Jan 2026 | $0.09 | $-0.01 | -10.53% | 830,720 | $0.09 | $0.10 | $0.09 |
| 29 Jan 2026 | $0.10 | $0.01 | 11.76% | 883,640 | $0.09 | $0.10 | $0.09 |
| 28 Jan 2026 | $0.09 | $-0.01 | -10.53% | 181,552 | $0.09 | $0.09 | $0.09 |
| 27 Jan 2026 | $0.10 | $0.00 | 0.00% | 417,347 | $0.10 | $0.10 | $0.09 |
| 23 Jan 2026 | $0.10 | $0.00 | 0.00% | 59,589 | $0.10 | $0.10 | $0.10 |
| 22 Jan 2026 | $0.10 | $0.01 | 10.99% | 603,960 | $0.09 | $0.10 | $0.09 |
| 21 Jan 2026 | $0.09 | $0.00 | 0.00% | 217,279 | $0.09 | $0.09 | $0.09 |
| 20 Jan 2026 | $0.09 | $-0.01 | -10.20% | 976,983 | $0.10 | $0.10 | $0.09 |
| 19 Jan 2026 | $0.10 | $0.01 | 11.11% | 249,788 | $0.09 | $0.10 | $0.09 |
| 16 Jan 2026 | $0.09 | $-0.01 | -10.00% | 1,421,945 | $0.11 | $0.11 | $0.09 |
| 15 Jan 2026 | $0.10 | $0.01 | 11.36% | 2,063,292 | $0.09 | $0.10 | $0.09 |
| 14 Jan 2026 | $0.09 | $0.00 | 0.00% | 1,023,897 | $0.08 | $0.09 | $0.08 |
| 13 Jan 2026 | $0.08 | $0.00 | 0.00% | 232,075 | $0.08 | $0.08 | $0.08 |
| 12 Jan 2026 | $0.08 | $0.01 | 13.33% | 778,414 | $0.08 | $0.08 | $0.08 |
| 09 Jan 2026 | $0.08 | $0.00 | 0.00% | 362,467 | $0.07 | $0.08 | $0.07 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 17 Sep 2025 | Richard Bund | Sell | 690,290 | $56,672 |
On-market trade.
|
| 10 Sep 2025 | Richard Bund | Sell | 1,829,460 | $156,541 |
On-market trade.
|
| 13 Aug 2025 | Pasquale (Paddy) Rombola | Issued | 300,000 | $25,500 |
Placement. As per announcement on 15-08-2025
|
| 13 Aug 2025 | Pasquale (Paddy) Rombola | Issued | 600,000 | $54,000 |
Placement.
|
| 13 Aug 2025 | Ian Frazer | Issued | 833,333 | $74,999 |
Placement.
|
| 13 Aug 2025 | Ian Frazer | Issued | 416,666 | $35,416 |
Placement. As per announcement on 15-08-2025
|
| 29 Apr 2025 | Hyungtae Kim | Expiry | 200,000 | $45,000 |
Options expired.
|
| 29 Apr 2025 | Richard Bund | Expiry | 200,000 | $45,000 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Pasquale (Paddy) Rombola | Non-Executive ChairmanNon-Executive Director | Jun 2017 |
Mr Rombola has over 30 years of corporate and financial experience in Australia, Asia and the United Kingdom. He spent 19 years in senior positions with Morgan Stanley and Deutsche Bank, including 7 years in the role of Managing Director. He is the Chair of Advantage Agriculture Pty Ltd, a private agribusiness company. He is member of Risk Committee.
|
| Professor Ian Hector Frazer | Non-Executive Deputy ChairmanNon-Executive Director | Jan 2017 |
Professor Frazer is an Emeritus Professor at the University of Queensland and is the former Chair of the Australian Medical research Advisory Board (AMRAB) which advises the Minister for Health and Aged Care on prioritising spending from the Medical Research Future Fund (MRFF). He is recognised as co-inventor of the technology enabling Gardasil the vaccine currently used worldwide to assist in the prevention of cervical cancer. He is Chair of Risk Committee.
|
| Professor Gene William Tyson | Non-Executive Director | Jan 2017 |
Professor Tyson is a Professor of Microbial Genomics at The Queensland University of Technology and is the Director of the Centre for Microbiome Research. He published the first paper regarding the use of metagenomic-sequencing for assessing microbial communities.
|
| Ms Jacqueline Fernley | Non-Executive Director | Sep 2022 |
Ms Fernley currently serves as the Chief Investment Officer (CIO) of Mason Stevens where she leads the asset management division of the firm. Prior to joining Mason Stevens, she held roles as Head of Equities at J B Were Limited, Head of Research at Wilson HTM and Australian Equity Portfolio Manager at Colonial First State Global Asset Management. She is also intimately involved in mentoring and supporting women in the financial services industry and ESG, regularly presenting to investment committees, boards, and management on the topics.
|
| Mr Stephane Chatonsky | Non-Executive Director | Nov 2025 |
Mr Chatonsky brings over 25 years of experience in venture capital, investment and corporate strategy. He has held various senior roles with Lazard, McKinsey & Company, Macquarie Bank, 4Cyte Pathology, Healius and LeapFrog Investments, and currently serves as a Non-Executive Director of Cerulea Clinical Trials and NeoBionica, and is a Senior Advisor to Heidi Health and Vexev.
|
| Dr Luke Reid | Chief Executive Officer |
-
|
|
| Mr James Heath | Chief Financial OfficerCompany Secretary | Aug 2024 |
-
|
| Luke Reid | Chief Executive Officer |
-
|
|
| James Heath | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| ACN 002 889 545 Pty Ltd | 98,597,402 | 19.14% |
| HSBC Custody Nominees (Australia) Limited | 53,750,159 | 10.44% |
| Ubs Nominees Pty Ltd | 38,721,316 | 7.52% |
| Sa Microba Holdings Pty Ltd | 33,480,799 | 6.50% |
| Macrogen Inc | 17,828,431 | 3.46% |
| Citicorp Nominees Pty Limited | 17,729,290 | 3.44% |
| Boysenholtz Pty Ltd | 17,178,431 | 3.34% |
| Genie Microbiome Pty Ltd | 15,920,000 | 3.09% |
| Mr Don Maree | 11,545,742 | 2.24% |
| Ginkgo Bioworks Inc | 10,886,385 | 2.11% |
| G & N Lord Superannuation Pty Ltd | 8,000,000 | 1.55% |
| J P Morgan Nominees Australia Pty Limited | 6,642,779 | 1.29% |
| Rombola Family Pty Ltd | 5,700,000 | 1.11% |
| Belgravia Strategic Equities Pty Ltd | 5,432,342 | 1.05% |
| Australian Direct Investments Pty Limited | 3,838,412 | 0.75% |
| BNP Paribas Nominees Pty Ltd | 3,528,900 | 0.69% |
| Uniquest Pty Ltd | 3,424,643 | 0.66% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 3,291,844 | 0.64% |
| RPMT Investments Pty Ltd | 3,288,715 | 0.64% |
| DERP Enterprises Pty Ltd | 2,902,500 | 0.56% |
